**Background of SERTAD3 Antibody**
SERTAD3 (SERTA domain-containing protein 3), also known as TRIP-Br3. is a member of the SERTA domain-containing protein family, which plays roles in transcriptional regulation and cell cycle control. It interacts with key regulators, such as E2F transcription factors and cyclin-dependent kinases (CDKs), influencing cell proliferation, apoptosis, and tumorigenesis. SERTAD3 is implicated in cancer progression, with studies showing its overexpression in various malignancies, including colorectal, breast, and liver cancers, where it correlates with poor prognosis and therapeutic resistance.
The SERTAD3 antibody is a critical tool for detecting and quantifying SERTAD3 protein expression in research. It enables the investigation of SERTAD3's functional roles, subcellular localization, and interaction partners via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercially available antibodies are typically validated for specificity and sensitivity, often targeting conserved regions of the protein. Recent studies highlight its potential as a biomarker for cancer diagnosis or a therapeutic target, driving interest in developing high-affinity antibodies for mechanistic and clinical studies. Understanding SERTAD3's regulatory networks through antibody-based assays remains vital for unraveling its contributions to cellular pathways and disease pathology.